gemtuzumab ozogamicin


Also found in: Wikipedia.

gemtuzumab ozogamicin

 [gem-too´zoo-mab″ o″zo-gah-mi´sin]
a recombinant DNA–derived monoclonal antibody conjugated with a cytotoxic antitumor antibiotic, used as an antineoplastic in the treatment of relapsed acute myelogenous leukemia, administered intravenously.

gemtuzumab ozogamicin

/gem·tu·zu·mab ozo·ga·mi·cin/ (gem-too´zoo-mab″ o″zo-kah-mi´sin) a recombinant DNA–derived monoclonal antibody conjugated with a cytotoxic antitumor antibiotic, used as an antineoplastic.

gemtuzumab ozogamicin

[gemto̅o̅′zo̅o̅mab′ o′zo-gah-mi′sin]
a recombinant DNA-derived monoclonal antibody conjugated with a cytotoxic antitumor antibiotic used as an antineoplastic in the treatment of relapsed acute myelogenous leukemia, administered intravenously.
Mentioned in ?
References in periodicals archive ?
The antineoplastic agents are alemtuzumab (Campath), bevacizumab (Avastin), cetuximab (Erbitux), gemtuzumab ozogamicin (Mylotarg), ibritumomab riuxetan (Zevalin), panitumumab (Vectibix), tositu-momab and iodine 131 (Bexxar), and trastuzumab (Herceptin).
MYLOTARG(R) (gemtuzumab ozogamicin) is contraindicated in patients with a known hypersensitivity to gemtuzumab ozogamicin or any of its components and in lactating mothers.
Effi cacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
Tokyo, Japan, July 27, 2005 - (JCNN) - Wyeth Japan announced on July 25 that it has obtained approval for Mylotarg, a proprietary preparation of gemtuzumab ozogamicin, from the Ministry of Health, Labor and Welfare.
Investigator Research on Several Pfizer Compounds to be Presented Including an ASH Plenary Presentation on Gemtuzumab Ozogamicin
He was also a key contributor to the discovery and development of gemtuzumab ozogamicin, known commercially as Mylotarg, the first monoclonal antibody approved by the Food and Drug Administration to treat acute myeloid leukemia.
A second phase II study from the MD Anderson Cancer Center concluded that the effect of fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) is a highly effective regimen and has resulted in high rate of relapse-free survival in patients with newly diagnosed patients with core-binding factor AML.
1304) Gemtuzumab Ozogamicin (Mylotarg(R)) as a Single Agent To Evaluate Safety and Determine Maximum Tolerated Dose (MTD) in Post Hematopoietic Stem Cell Transplant Patients with Relapsed, CD33+Acute Myeloid Leukemia (AML).
In this role, she led late-stage clinical development for bosutinib and gemtuzumab ozogamicin.
Azacitidine Plus Gemtuzumab Ozogamicin (GO): A Novel Combination in the Treatment of AML and High-Risk MDS in the Elderly Abstract ID: 1981 Sucha Nand, et al.
Patients given the new type of "smart drug" called Gemtuzumab Ozogamicin (GO) as well as chemotherapy were 22% less likely to relapse and around 13% less likely to die from their disease.
The research team studied more than 1,000 patients who received a combination of chemotherapy and the drug Gemtuzumab Ozogamicin, which is also known as Mylotarg.